The FDA authorizes the first e-cigarette; an FDA meeting will discuss mix-and-match booster vaccines; OSHA submitted the initial text of an emergency vaccine rule to the OMB for review.
On Tuesday, the FDA issued its first marketing authorization for an e-cigarette, saying the vaping device can help smokers cut back on conventional cigarettes. However, the agency also stressed that e-cigarettes are neither safe nor approved by it, and nonsmokers should not start using them. This authorization only applies to the Vuse Solo closed ENDS e-cigarette and its tobacco-flavored nicotine cartridges, with the agency saying its decision was based on data from manufacturer RJR Vapor Company that showed this e-cigarette helped smokers significantly reduce their cigarette consumption or quit smoking cigarettes. The FDA is currently reviewing the company’s request to sell a menthol-flavored nicotine formula, after rejecting 10 other flavors. Just last month, the FDA failed to meet the deadline set by a federal judge to decide which e-cigarettes can remain on the market.
FDA scientists did not take a clear position on whether the agency should authorize booster shots of the Moderna COVID-19 vaccine, STAT News reported. In documents posted October 12, ahead of 2-day meeting on Moderna and Johnson & Johnson boosters (J&J), the FDA made a case both for and against the authorization and need for a third dose of the Moderna vaccine. The meeting will also discuss a study by the National Institutes of Health, which analyzed the effects of mix-and-match boosters. Meanwhile, The New York Times reports that J&J data are insufficient to support the pharma giant’s application for a booster for its 1-shot COVID-19 vaccine, citing the psVNA assay it used to gauge the immune booster response lacked sensitivity and the FDA’s questioning if the data paint a reliable picture of immune response.
The Occupational Safety and Health Administration (OSHA) submitted the initial text of an emergency vaccine rule to the Office of Management and Budget (OMB) for review, bringing President Joe Biden’s vaccine mandate for large businesses a step closer to reality, FOX News reported. This comes a month after Biden announced businesses with more than 100 employees will be required to mandate COVID-19 vaccines or administer weekly tests and to pay employees for time off to get vaccinated and recover from the adverse effects. The rule will go into effect after the OMB finishes its review and it is published in the federal register.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
2 Commerce Drive
Cranbury, NJ 08512